Active — Not RecruitingPhase 2

Daily Topical Rapamycin for Vitiligo

United States20 participantsStarted 2022-07-28

Plain-language summary

In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.

Who can participate

Age range13 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients 13 years of age and older * Patients with nonsegmental vitiligo Exclusion Criteria: * Patients with segmental or mucosal vitiligo * Patients with contraindication to use of rapamycin * Patients with history of transplant * Patients with a history of natural immunodeficiency * Patients with a history of artificially induced immunodeficiency * Patients with a history of a serious or life-threatening infection * Patients taking CYP3A4 inhibiting medications * Patients taking strong CYP3A4 inducers * Patients undergoing current treatment for vitiligo * Women that are or may become pregnant

What they're measuring

Number of lesions with no response

Timeframe: 6 months

Number of lesions with partial response

Timeframe: 6 months

Numbers of lesions with complete response

Timeframe: 6 months

Trial details

NCT IDNCT05342519

SponsorMedical University of South Carolina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-01

View on ClinicalTrials.gov More Vitiligo trials